US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jupiter Neurosciences

0.6205

+0.00050.08%

Post-market: 0.65000.0295+4.75%18:23 EDT

Volume:19.46K

Turnover:11.94K

Market Cap:20.54M

PE:-7.32

High:0.6439

Open:0.6100

Low:0.5889

Close:0.6200

Loading ...

Overview Company News Filings

BRIEF-Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development

Jupiter Neurosciences: to Initiate Jns115 Parkinson’s Phase 2a Trial in Q3 2025

THOMSON REUTERS

Jupiter Neurosciences Inc - Does Not Anticipate Impact From U.S. Tariffs on Clinical-Stage Prescription Product Development

THOMSON REUTERS

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

BRIEF-Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products

Jupiter Neurosciences Inc - First Three Products Expected to Launch in Q3 2025

THOMSON REUTERS

Jupiter Neurosciences and Aquanova Ag Announce Strategic Collaboration to Develop Longevity and Healthspan Products

THOMSON REUTERS

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules

MT Newswires Live

Jupiter Neurosciences Announces Jotrol Manufacturing Agreement With Catalent to Support Phase 2a Parkinson’s Trial

THOMSON REUTERS

Jupiter Neurosciences- Under Terms, Catalent to Manufacture Clinical Batches of Jotrol for Parkinson's Study

THOMSON REUTERS

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study

MT Newswires Live

Jupiter Neurosciences Partners With Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

THOMSON REUTERS

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures

MT Newswires Live

Investors Look Ahead to PMI, Home Price Data as US Futures Tread Water in Friday's Premarket

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/JUNS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"JUNS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JUNS\",,,,,undefined,":{"symbol":"JUNS","market":"US","secType":"STK","nameCN":"Jupiter Neurosciences","latestPrice":0.6205,"timestamp":1745265600000,"preClose":0.62,"halted":0,"volume":19461,"hourTrading":{"tag":"盘后","latestPrice":0.65,"preClose":0.6205,"latestTime":"18:23 EDT","volume":220,"amount":142.080004,"timestamp":1745274230078},"delay":0,"floatShares":15166897,"shares":33103860,"eps":-0.084759,"marketStatus":"Post-Mkt","change":0.0005,"latestTime":"04-21 18:24:52 EDT","open":0.61,"high":0.6439,"low":0.5889,"amount":11935.730999399999,"amplitude":0.08871,"askPrice":0.65,"askSize":1000,"bidPrice":0.6,"bidSize":1600,"shortable":0,"etf":0,"ttmEps":-0.084759,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"listingDate":1733202000000,"exchange":"NASDAQ","adjPreClose":0.62,"preHourTrading":{"tag":"盘前","latestPrice":0.6,"preClose":0.62,"latestTime":"09:17 EDT","volume":25,"amount":15.035000000000002,"timestamp":1745241427360},"postHourTrading":{"tag":"盘后","latestPrice":0.65,"preClose":0.6205,"latestTime":"18:23 EDT","volume":220,"amount":142.080004,"timestamp":1745274230078},"volumeRatio":0.062057},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JUNS\",,,,,undefined,":{"symbol":"JUNS","floatShares":15166897,"roa":"-60.84%","roe":"--","lyrEps":-0.084759,"volumeRatio":0.062057,"shares":33103860,"dividePrice":0,"high":0.6439,"amplitude":0.08871,"preClose":0.62,"low":0.5889,"week52Low":0.51,"pbRate":"4.92","psRate":"88.05","week52High":19.51,"institutionHeld":0,"latestPrice":0.6205,"committee":0.230769,"eps":-0.084759,"divideRate":0,"volume":19461,"delay":0,"ttmEps":-0.084759,"open":0.61,"prevYearClose":10.7,"prevWeekClose":0.62,"prevMonthClose":0.61,"prevQuarterClose":0.61,"fiveDayClose":0.5314,"twentyDayClose":0.755,"sixtyDayClose":1.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"JUNS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525981850","title":"BRIEF-Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2525981850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525981850?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:42","pubTimestamp":1744119732,"startTime":"0","endTime":"0","summary":"BRIEF-Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product DevelopmentApril 8 (Reuters) - Jupiter Neurosciences Inc JUNS.O:JUPITER NEUROSCI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2525645899","title":"Jupiter Neurosciences: to Initiate Jns115 Parkinson’s Phase 2a Trial in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525645899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525645899?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:07","pubTimestamp":1744114054,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2525089953","title":"Jupiter Neurosciences Inc - Does Not Anticipate Impact From U.S. Tariffs on Clinical-Stage Prescription Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2525089953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525089953?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:07","pubTimestamp":1744114054,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JUNS","BK4007"],"gpt_icon":0},{"id":"2525589955","title":"Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2525589955","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525589955?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL JOTROL development programs remain tariff-exempt; consumer longevi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057560/0/en/Jupiter-Neurosciences-Highlights-Upcoming-Milestones-in-Shareholder-Letter.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2517430492","title":"Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430492","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517430492?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:10","pubTimestamp":1741363800,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESS Newswire / March 7, 2025 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp.  and Jupiter Neurosciences, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 8, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Christer Rosén, Chairman & CEO of Jupiter Neurosciences, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's flagship product, JOTROL, a first-of-its-kind resveratrol formulation that leverages patented micellar technology to deliver therapeutic doses with nine times greater bioavailability than traditional resveratrol products, all without the gastrointestinal side effects that have historically hindered its clinical use. This breakthrough positions JOTROL to address significant unmet needs across CNS disorders and rare diseases, including Alzheimer's, Parkinson's, MPS-I, Friedreich's A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alliance-entertainment-jupiter-neurosciences-interviews-161000599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AENT","BK4187","BK4581","BK4604","BK4555","BK4590","AENTW","03160","BK4585","BK4159","BK4144","TM","TV","BK4588","BK4007","BK4099","BK4561","AIRI","BK4100","ET","JUNS"],"gpt_icon":0},{"id":"2516676975","title":"BRIEF-Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676975","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676975?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:18","pubTimestamp":1741094330,"startTime":"0","endTime":"0","summary":"BRIEF-Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan ProductsMarch 4 (Reuters) - Jupiter Neurosciences Inc JUNS.O:JUPITER NEUROSCIENCES AND ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA8NHXKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2516675439","title":"Jupiter Neurosciences Inc - First Three Products Expected to Launch in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675439?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA8NHXKW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2516267512","title":"Jupiter Neurosciences and Aquanova Ag Announce Strategic Collaboration to Develop Longevity and Healthspan Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2516267512","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516267512?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA8NHXKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JUNS","BK4007"],"gpt_icon":0},{"id":"2516726675","title":"Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2516726675","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516726675?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"First three consumer products expected to launch in Q3 2025, providing near-term revenue growth Jupiter, Florida, March  04, 2025  (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036479/0/en/Jupiter-Neurosciences-and-Aquanova-AG-Announce-Strategic-Collaboration-to-Develop-Longevity-and-Healthspan-Products.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","BK4210","JUNS","BK4190","BK4007","CNS","DTC","BK4135"],"gpt_icon":0},{"id":"2508457008","title":"Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’","url":"https://stock-news.laohu8.com/highlight/detail?id=2508457008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508457008?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:30","pubTimestamp":1738679421,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences (JUNS) issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-says-volatility-appears-to-be-driven-by-misconceptions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-says-volatility-appears-to-be-driven-by-misconceptions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2508524234","title":"Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2508524234","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508524234?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:25","pubTimestamp":1738679100,"startTime":"0","endTime":"0","summary":"Jupiter, Florida, Feb.  04, 2025  (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL, a patented res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/04/3020449/0/en/Jupiter-Neurosciences-Addresses-Market-Volatility-as-it-Remains-Focused-on-Advancing-Clinical-and-Commercial-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2508140617","title":"Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2508140617","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508140617?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:10","pubTimestamp":1738599016,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences  said Monday that it signed an agreement with Catalent Pharma Solutions for the production of Jotrol softgel capsules for Jupiter's upcoming phase 2a clinical trial in Parkinson's disease.Jotrol is Jupiter's oral formulation of resveratrol and under the deal, Catalent will manufacture clinical batches of Jotrol using a softgel formulation, according to the statement. No financial details were disclosed.Jupiter said the production will include active and placebo batches for its planned Parkinson's study, which will evaluate Jotrol's safety, tolerability, and pharmacokinetics in patients with Parkinson's disease over a three-month period.Shares of Jupiter Neurosciences were down more than 9% in recent Monday trading.Price: 0.93, Change: -0.10, Percent Change: -9.32","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTLT","BK4585","BK4588","BK4530","JUNS","BK4007"],"gpt_icon":0},{"id":"2508110504","title":"Jupiter Neurosciences Announces Jotrol Manufacturing Agreement With Catalent to Support Phase 2a Parkinson’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508110504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508110504?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:00","pubTimestamp":1738587600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA3GLFQ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2508109001","title":"Jupiter Neurosciences- Under Terms, Catalent to Manufacture Clinical Batches of Jotrol for Parkinson's Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2508109001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508109001?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:00","pubTimestamp":1738587600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA3GLFQ4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JUNS","BK4007"],"gpt_icon":0},{"id":"2508239110","title":"Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508239110","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508239110?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:00","pubTimestamp":1738587600,"startTime":"0","endTime":"0","summary":"Jupiter, Florida, Feb. 03, 2025  -- Jupiter Neurosciences, Inc.  , a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced it has entered into an agreement with Catalent Pharma Solutions, LLC  for the production of JOTROL softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease.Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation. The production will include both active and placebo batches for the Parkinson’s study. This manufacturing initiative will be conducted under current Good Manufacturing Practices  to meet regulatory and clinical standards.“Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson’s disease,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Catalent’s indus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jupiter-neurosciences-announces-jotrol-manufacturing-130000922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JUNS","BK4007","BK4139","BK4530","CDMO","CTLT","BK4585","BK4588"],"gpt_icon":0},{"id":"2507675983","title":"Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2507675983","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507675983?lang=en_us&edition=fundamental","pubTime":"2025-01-31 01:07","pubTimestamp":1738256876,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences  said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.Shares of Jupiter were down more than 5% in recent trading.Price: 1.15, Change: -0.07, Percent Change: -5.74","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JUNS","BK4007"],"gpt_icon":0},{"id":"2507402026","title":"Jupiter Neurosciences Partners With Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2507402026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507402026?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA2HGT47:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2507819628","title":"Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2507819628","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507819628?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"Jupiter, Florida, Jan. 30, 2025  -- Jupiter Neurosciences, Inc.  , a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC  to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease.JOTROL’s innovative micellar formulation overcomes the historical limitations of resveratrol by achieving significantly enhanced bioavailability while minimizing gastrointestinal side effects. Preclinical studies have demonstrated JOTROL’s potential in mitigating key biomarkers associated with neurodegeneration, supporting its potential application in Parkinson’s disease and other central nervous system  disorders.Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL, is an enhanced orally administered resveratrol f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jupiter-neurosciences-partners-zina-biopharmaceuticals-130000589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JUNS","BK4007","CNS","BK4135"],"gpt_icon":0},{"id":"2505865764","title":"Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures","url":"https://stock-news.laohu8.com/highlight/detail?id=2505865764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505865764?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:29","pubTimestamp":1737728956,"startTime":"0","endTime":"0","summary":"US stocks look set to open slightly lower in Friday's trading session as investors await manufacturing and services data, as well as existing home sales figures set for release later in the morning.Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4116","BK4149","LITM","BK4205","EVAX","BK4192","BK4139","BK4007","BK4548","BK4588","LU1720051017.SGD","BK4009","LU1861558580.USD","LU1861559042.SGD","BK4585","BK4551","BK4233","BK4211","ISBC","LU1720051108.HKD","ALUR","TWLO","MCTR","STBX","CKX","BK4168","FUND","LU1548497426.USD","BK4528","JUNS","HYZN","LU2357305700.SGD"],"gpt_icon":1},{"id":"2505852749","title":"Investors Look Ahead to PMI, Home Price Data as US Futures Tread Water in Friday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2505852749","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505852749?lang=en_us&edition=fundamental","pubTime":"2025-01-24 21:10","pubTimestamp":1737724249,"startTime":"0","endTime":"0","summary":"US stock futures were treading water in Friday's premarket session ahead of a slate of economic data coming out later in the morningThe Dow Jones Industrial Average futures were down 0.25%, S&P 500 fu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4195","BK4211","EZPW","MCTR","CFA.SI","ALUR","BK4192","JUNS","BK4139","BK4009","HBCP","STBX","BK4007","ISBC","BK4166","EVAX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/JUNS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"JUNS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"JUNS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1734840000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/JUNS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"JUNS","date":"2025-04-17","current":-9.589382,"percent":0.855556,"low":-282.025188,"twenty":-146.359819,"median":-21.385059,"eighty":-15.098093,"high":-7.210695,"avg":-71.929367,"sd":84.237816,"marketCap":23394497},"quantilePoints":[{"date":"2022-09-20","current":-11.989719,"twenty":-11.989719,"median":-11.989719,"eighty":-11.989719,"marketCap":56920086},{"date":"2024-12-06","current":-79.299938,"twenty":-65.837894,"median":-45.644828,"eighty":-25.451763,"marketCap":200217355},{"date":"2024-12-13","current":-200.137938,"twenty":-144.536832,"median":-104.691543,"eighty":-83.727192,"marketCap":505310467},{"date":"2024-12-20","current":-141.411712,"twenty":-153.808024,"median":-137.570417,"eighty":-102.087276,"marketCap":357037845},{"date":"2024-12-27","current":-282.025188,"twenty":-200.137938,"median":-143.885765,"eighty":-104.691543,"marketCap":378377119},{"date":"2025-01-03","current":-258.831516,"twenty":-265.592225,"median":-152.284527,"eighty":-119.900464,"marketCap":347259491},{"date":"2025-01-10","current":-213.431136,"twenty":-260.904142,"median":-179.564226,"eighty":-125.499639,"marketCap":286348389},{"date":"2025-01-17","current":-105.358491,"twenty":-256.166711,"median":-158.990515,"eighty":-125.499639,"marketCap":141353482},{"date":"2025-01-24","current":-35.777474,"twenty":-238.993524,"median":-149.745367,"eighty":-106.641545,"marketCap":48000597},{"date":"2025-01-31","current":-27.635014,"twenty":-214.911583,"median":-143.885765,"eighty":-82.913302,"marketCap":37076323},{"date":"2025-02-07","current":-25.167602,"twenty":-213.431136,"median":-133.729123,"eighty":-31.089391,"marketCap":33765937},{"date":"2025-02-14","current":-20.913783,"twenty":-212.444171,"median":-125.200148,"eighty":-25.907825,"marketCap":28058831},{"date":"2025-02-21","current":-20.64977,"twenty":-210.716983,"median":-106.962309,"eighty":-24.176689,"marketCap":27704620},{"date":"2025-02-28","current":-16.506986,"twenty":-208.84175,"median":-101.436209,"eighty":-21.463029,"marketCap":22146482},{"date":"2025-03-07","current":-16.284919,"twenty":-204.258528,"median":-57.538706,"eighty":-20.655198,"marketCap":21848547},{"date":"2025-03-14","current":-15.006799,"twenty":-191.908453,"median":-32.569838,"eighty":-17.607452,"marketCap":20133767},{"date":"2025-03-21","current":-19.196465,"twenty":-158.15715,"median":-28.621979,"eighty":-16.511921,"marketCap":25754803},{"date":"2025-03-28","current":-18.327936,"twenty":-153.808024,"median":-25.414343,"eighty":-16.605682,"marketCap":24589547},{"date":"2025-04-04","current":-8.521483,"twenty":-149.207844,"median":-24.548282,"eighty":-16.107265,"marketCap":20789224},{"date":"2025-04-11","current":-7.449513,"twenty":-146.918166,"median":-22.108011,"eighty":-15.634508,"marketCap":18174019},{"date":"2025-04-17","current":-9.589382,"twenty":-146.359819,"median":-21.385059,"eighty":-15.098093,"marketCap":23394497}],"updateTime":1745273848521}}}